Prodrugs pp 1313-1321

Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Case Study: Omeprazole (Prilosec®)

  • Jeffrey N. Hemenway

Abstract

Omeprazole, currently marketed as Prilosec and generic omeprazole, has been shown to reduce gastric acid secretion in animals and man. It reduces the secretion of acid by inhibiting the proton pump of the parietal cell (Fellenius et al., 1981). Omeprazole was not designed as a prodrug. It was first synthesized by Junggren et al. (1981) along with 29 other derivatives of substituted 2-(2-benzimidazolyl)-pyridines and was found to have more potent gastric acid secretion inhibitory effects in dogs than did previously tested structurally related compounds. However, omeprazole was later found not to be the active inhibitor of the proton pump per se. Instead, it acts as a prodrug and is converted to the active inhibitor in the acidic compartments of the parietal cell, near the enzymes it inhibits (Lindberg et al., 1986).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersson, T. Omeprazole Drug Interaction Studies. Clin Pharmacokinet 1991;21:195–212PubMedCrossRefGoogle Scholar
  2. Andersson T. Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors. Focus on Omeprazole, Lansoprazole and Pantoprazole. Clin Pharmacokinet 1996; 31:9–28 Erratum in: Clin Pharmacokinet 1996; 31: 274PubMedGoogle Scholar
  3. Arnold R, and Koop H. Omeprazole: Long-Term Safety. Digestion 1989; 44suppl 1: 77–86PubMedGoogle Scholar
  4. Baldwin JE, Adlington RM, and Crouch NP. Process for the Preparation of Omeprazole and Intermediate Compounds. Eur Patent EP 899268, 1999: 8 pGoogle Scholar
  5. Brandstrom AE. Method for Synthesis of Omeprazole. Int Patent WO 9118895 1991: 11 pGoogle Scholar
  6. Brandstrom AE, Lindberg P, and Junggren U. Structure activity relationships of substituted benzimidazoles. Scand J Gastroenterol Suppl 1985; 108:15–22PubMedCrossRefGoogle Scholar
  7. Brandstrom AE, Lindberg P, Bergman NA, Alminger T, Ankner K, Junggren U, Lamm B, Nordberg P, and Erickson M. Chemical Reactions of omeprazole and Omeprazole Analogs. I. A Survey of the Chemical Transformations of Omeprazole and its Analogs. Acta Chem Scand 1989; 43:536–548Google Scholar
  8. Carlsson E. A Review of the Effects of Long-Term Acid Inhibition in Animals. Scand J Gastroenterol Suppl 1989; 166:19–23PubMedCrossRefGoogle Scholar
  9. Cederberg C, Andersson T, and Skanberg I. Omeprazole: Pharmacokinetics and Metabolism in Man. Scand J Gastroenterol Suppl 1989; 166:33–40; discussion 41–42PubMedCrossRefGoogle Scholar
  10. Clissold SP, and Campoli-Richards DM. Omeprazole. A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Peptic Ulcer Disease and Zollinger-Ellison Syndrome. Drugs 1986; 32:15–47; Erratum in: Drugs 1986; 32:383PubMedCrossRefGoogle Scholar
  11. Correia PB, Romao CC, Correia LB, Pereira MF, Fernandes AC, Borges JE, Tavares R, Costa MDC, and Teixeira F. New Method for the Preparation of the Anti-Ulcer Compounds Omeprazole, Lansoprazole and Pantoprazole. Int Patent WO 2003097606, 2003:21 pGoogle Scholar
  12. Dent J. Review Article: Pharmacology of Esomeprazole and Comparisons with Omeprazole. Aliment Pharmacol Ther 2003; 17Suppl 1:5–9PubMedCrossRefGoogle Scholar
  13. Ekman L, Hansson E, Havu N, Carlsson E, and Lundberg C. Toxicological Studies on Omeprazole. Scand J Gastroenterol Suppl 1985; 108:53–69PubMedCrossRefGoogle Scholar
  14. Evans HJ. Tests for Genotoxicity: Principles and Findings in Relation to Omeprazole. Digestion 1990; 47Suppl 1:45–48PubMedGoogle Scholar
  15. Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjostrand SE, and Wallmark B. Substituted Benzimidazoles Inhibit Gastric Acid Secretion by Blocking (H+ + K+)ATPase. Nature 1981; 290:159–161PubMedCrossRefGoogle Scholar
  16. Hassan-Alin M, Niazi M, and Röhss K. Esomeprazole, the S-isomer of Omeprazole is Optically Stable in Humans. Gastroenterol 2000; 118Suppl 2:A1244–1245CrossRefGoogle Scholar
  17. Hetzel DJ. Controlled Clinical Trials of Omeprazole in the Long-Term Management of Reflux Disease. Digestion 1992; 51Suppl 1:35–42PubMedGoogle Scholar
  18. Howden CW. Clinical Pharmacology of Omeprazole. Clin Pharmacokinet 1991;2:38–49CrossRefGoogle Scholar
  19. Humphries TJ. Clinical Implications of Drug Interactions with the Cytochrome P-450 Enzyme System Associated with Omeprazole. Dig Dis Sci 1991;36:1665–1669PubMedCrossRefGoogle Scholar
  20. Joelson S, Joelson IB, Lundborg P, Walan A, and Wallander MA. Safety Experience from Long-Term Treatment with Omeprazole. Digestion 1992; 51Suppl1:93–101; Erratum in: Digestion 1992; 53:213PubMedCrossRefGoogle Scholar
  21. Junggren UK, and Sjöstand SE. Gastric Acid Secretion Inhibiting Substituted 2-(2-Benzimidazolyl)-pyridines, Pharmaceutical Preparations Containing Same, and Methods for Inhibiting Gastric Acid Secretion. US Patent 4255431, 1981:10pGoogle Scholar
  22. Langtry HD, and Wilde MI. Omeprazole A Review of its Use in Helicobacter Pylori Infection, Gastro-Esophageal Reflux Disease and Peptic Ulcers Induced by Nonsteroidal Anti-Inflammatory Drugs. Drugs 1998; 56:447–486PubMedCrossRefGoogle Scholar
  23. Lindberg P, Nordberg P, Alminger T, Brandstrom A, and Wallmark B. The Mechanism of Action of the Gastric Acid Secretion Inhibitor Omeprazole. J Med Chem 1986; 29:1327–1329PubMedCrossRefGoogle Scholar
  24. Logan RPH. The Chemotherapeutic Effects of H+/K+ Inhibitors on Helicobacter Pylori Infection. Pharmacol Ther 1996; 69: 79–83PubMedCrossRefGoogle Scholar
  25. McTavish D, Buckley MM, and Heel RC. Omeprazole. An Updated Review of its Pharmacology and Therapeutic Use in Acid-Related Disorders. Drugs 1991;42:138–170PubMedGoogle Scholar
  26. Nelis GF. Safety Profile of Omeprazole. Adverse Events with Short-term Treatment. Digestion 1989; 44Suppl 1:68–76PubMedGoogle Scholar
  27. Senn-Bilfinger J, Krueger U, Sturm E, Figala V, Klemm K, Kohl B, Rainer G, Schaefer H, and Blake TJ. (H+−K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 2. The Reaction Cascade Induced by Treatment with Acids. Formation of 5H-Pyrido[1′,2′:4,5][1,2,4]Thiadiazino[2,3-a]benzimidazol-13-ium Salts and Their Reactions with Thiols. J Org Chem 1987;52: 4582–4592CrossRefGoogle Scholar
  28. Slemon C, and Macel B. Preparation of Omeprazole and Lansoprazole Via Oxidation of Amide Thioether, Hydrolysis of Sulfinyl Amide, and Decarboxylation of Sulfinyl Carboxylate. US Patent 5374730, 1994:6 pGoogle Scholar
  29. Smahovsky V, Oremus V, Heleyova K, Zlatoidsky P, Gattnar O, Varga I, Stalmach V, Jezek L, Slovakofarma AS, Slovakia, Gattnar O, Stalmach, and Valdemar JL. Method of Omeprazole Preparation. Int Patent WO 9809962 1998:10 pGoogle Scholar
  30. Solvell L. The Clinical Safety of Omeprazole. Digestion 1990; 47Suppl 1:59–63; discussion 76PubMedGoogle Scholar
  31. Spencer CM, and Faulds D. Esomeprazole. Drugs 2000; 60:321–329PubMedCrossRefGoogle Scholar
  32. Sturm E, Krueger U, Senn-Bilfinger J, Figala V, Klemm K, Kohl B, Rainer G, Schaefer H, Blake, and Timothy J. (H+−K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 1. Their Reaction with Thiols Under Acidic Conditions. Disulfide Containing 2-Pyridiniobenzimidazolides as Mimics for the Inhibited Enzyme. J Org Chem 1987; 52: 4573–4581CrossRefGoogle Scholar
  33. Ulmer HJ, Beckerling A, and Gatz G. Recent Use of Proton Pump Inhibitor-based Triple Therapies for the Eradication of H Pylori: A Broad Data Review. Helicobacter 2003; 8: 95–104PubMedCrossRefGoogle Scholar
  34. Wallmark B, Brandstrom A, and Larsson H. Evidence for Acid-induced Transformation of Omeprazole into an Active Inhibitor of Proton-Potassium ATPase within the Parietal Cell. Biochim et Biophys Acta 1984; 778:549–558CrossRefGoogle Scholar
  35. Wilde MI, and McTavish D. Omeprazole. An Update of its Pharmacology and Therapeutic Use in Acid-related Disorders. Drugs 1994; 48:91–132PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Jeffrey N. Hemenway
    • 1
  1. 1.Bristol-Myers SquibbNew BrunswickUSA

Personalised recommendations